# A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

> **NCT03406780** · PHASE2 · COMPLETED · sponsor: **Capricor Inc.** · enrollment: 20 (actual)

## Conditions studied

- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Muscular Disorders, Atrophic
- Muscular Diseases
- Neuromuscular Diseases
- Nervous System Diseases
- Genetic Diseases, X-Linked
- Genetic Diseases, Inborn

## Interventions

- **BIOLOGICAL:** CAP-1002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03406780
- **Lead sponsor:** Capricor Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-04
- **Primary completion:** 2020-03-10
- **Final completion:** 2020-03-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03406780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03406780, "A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03406780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*